L.K. has received research grants from Allergy Therapeutics/Bencard, Great Britain/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden; Bionorica, Germany; BioNTech, Germany; Biomay, Austria; Blueprint, USA; Boehringer Ingelheim, Germany; Celltrion, South Korea; Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; Viatris/Mylan, USA; Novartis, Switzerland; Leti, Spain; ROXALL, Germany; GlaxoSmithKline (GSK), Great Britain; Sanofi, France; Stallergenes, France; Thermofisher, USA and/or has served on the speaker's bureau or was consulting for the above mentioned pharmaceutical companies. L.K. is the current President of German Society of Allergology AeDA, Governance Committee Board Member and ENT Section Board Member of the European Academy for Allergy and Clinical Immunology (EAACI), Vice-President of German Academy for Allergy and Environmental Medicine, Head of the Steering Committee of the German National CRS Registry (GENRE-CRS) and Editor-in-Chief of AllergoJournal and AllergoJournal International. M.M. has been an investigator for Amgen, Astra Zeneca, Celldex, Escient, Galderma, Incyte, Jasper, Novartis, Sanofi, Third Harmonic Bio, and received honoraria as a speaker and/or advisor from AbbVie, Advanz, ALK Abelló, Allegria, Almirall, Amgen, Argenx, Astra Zeneca, Astria, Attovia, Bambusa, Berlin-Chemie, Blueprint, Celldex, Celltrion, DeepApple, Enanta, Escient, FatiAbGen, Ga2len, Galderma, Granular, GSK, Incyte, Japan Tobacco, Jasper, Lilly, Lycia, Novartis, Pfizer, Pharvaris, Proinnovera, Regeneron, Sanofi, Santa Ana Bio, Septerna, Teva, Third Harmonic Bio, Vifor. T. Zuberbier has received institutional funding for research and/or honoria for lectures and/or consulting from Amgen, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, Blueprint Medicine, FAES, HAL, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva and UCB, Uriach, and Viatris; in addition, he is a member of ARIA, DGAKI, ECARF, GA2LEN and WAO. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Klimek et al. (Fri,) studied this question.